Table 1.
Studies investigating BTAs in the prevention of bone metastases from breast and prostate cancer (adapted from Casimiro et al. 75)
| Drug | Number of patients | Bone recurrence | Disease recurrence | Cancer mortality |
|---|---|---|---|---|
| Breast cancer | ||||
| BPs (EBCTCG) 46 | Overall n = 18 766 | HR 0.83 (95% CI 0.73–0.94);P = 0.004 | HR 0.94 (95% CI 0.87–1.01);P = 0.08 | HR 0.91 (95% CI 0.83–0.99);P = 0.04 |
| Postmenopausal n = 7388 | ||||
| HR 0.72 (95% CI 0.60–0.86);P = 0.0002 | HR 0.86 (95% CI 0.78–0.94);P = 0.002 | HR 0.82 (95% CI 0.73–0.93);P = 0.002 | ||
| Denosumab (ABCSG‐18) 50, 51 | Postmenopausal; n = 3425 | HR 0.97 95% CI 0.82–1.14,P = 0.70 | HR 0.82 (95% 0.69–0.98,Cox P = 0.026) | HR 1.03 95% CI 0.85–1.25 |
| Overall n = 4509 Postmenopausal; n = 2149 | ||||
| HR 1.04 95% CI 0.91–1.19,P = 0.57 | ||||
| (D‐CARE) 52 | ||||
| Prostate cancer | ||||
| Zoledronic acid (ZEUS) 57 | High risk disease; 1393 | 14.7 vs. 13.2% in the control group at 4.8 year; (log‐rank: P = 0.65) | 116 vs. 122 deaths in the control group; log‐rank P = 0.76 | |
| (RADAR) 58 | Locally advanced disease treated with RT and ADT ± ZA; n = 1071 | No difference in prostate cancer‐specific mortality | ||